The International Society for Pharmacoeconomics and Outcomes Research is reminding members about the June 25 deadline to submit comments for the society to send in response to the Health and Human Services’ call for comments on its drug pricing blueprint.
ISPOR announced its plans to submit comments on some questions included in pages 20-40 of the “HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs,” including:
- Underpricing or Cost-Shifting, page 21. Cost-shifting, as can be caused by the Medicaid best price restrictions, has the potential to distort resource utilization and result in inefficient care – is there evidence of this actually having happened due to Medicaid best pricing?
- Biosimilar Development, page 23. Evidence – and the uncertainty inherent in it – about relative efficacy, immunogenicity, and tolerability, and how they may affect treatment patterns (e.g., when cycling is relevant) need to be available for informed decision-making, especially when there are not large differences in pricing.
- Value-Based Arrangements and Price Reporting, page 25. While some of the specific price reporting issues discussed here may not be relevant, a discussion of value-based arrangements in general could provide good context here.
ISPOR members can find more information by clicking here.